| I-01 Joăo Abrantes ADaMO: End-to-end automation of Pharmacometric modelling in drug development, from dataset building to output generation Wednesday 09:45-11:15 |
| I-02 Nicolas Azzopardi Mechanistic model of contrast-enhanced ultrasound in colorectal cancer metastasis. Wednesday 09:45-11:15 |
| I-03 Freya Bachmann Computing Optimal Drug Dosing with OptiDose: Implementation in NONMEM Wednesday 09:45-11:15 |
| I-10 Chao Chen The area under the effect curve as a preclinical-to-clinical translation tool for predicting therapeutic dose of anti-infectives Wednesday 09:45-11:15 |
| I-11 Henrik Cordes Species-specific Expression Databases for Physiologically Based Pharmacokinetic Modeling Wednesday 09:45-11:15 |
| I-20 Mélanie Guhl Computation of standard errors at finite distance in non linear mixed effects models Wednesday 09:45-11:15 |
| I-24 Laura Iavarone Application of the Area Under the Effect Curve as in vivo efficacy driver in Visceral Leishmaniasis Wednesday 09:45-11:15 |
| I-25 Woojin Jung Containerized NONMEM and its assistant software in R development environment Wednesday 09:45-11:15 |
| I-28 Silvia Maria Lavezzi Translational pharmacology benchmarking of a novel drug candidate for an autoimmune disease Wednesday 09:45-11:15 |
| I-32 Nicolas Luyckx Campsis: A generic, easy-to-use and intuitive PK/PD simulation platform based on R packages RxODE and mrgsolve Wednesday 09:45-11:15 |
| I-35 Frano Mihaljevic Development of a level A in vitro/in vivo correlation (IVIVC) using applications of the MonolixSuite Wednesday 09:45-11:15 |
| I-39 Marije Otto Application of Item Response Theory in Early Phase Clinical Trials: Utilization of a Reference Model to Analyse the Montgomery-Ĺsberg Depression Rating Scale. Wednesday 09:45-11:15 |
| I-40 Theodoros Papathanasiou PKPD Exploratory Graphics (xGx) Cheat Sheet Wednesday 09:45-11:15 |
| I-44 Thao Nguyen Pham Combining aggregate data and individual patient/subject data in model-based meta-analysis: An illustrative case study of tofacitinib in rheumatoid arthritis patients Wednesday 09:45-11:15 |
| I-48 Christelle Rodrigues Using preclinical data to predict human pharmacokinetics of monoclonal antibodies for first-in-human dose setting: A review of five internal case studies Wednesday 09:45-11:15 |
| I-51 Sergio Sánchez Herrero Ground-breaking software for modelling, simulation, optimization, estimation and validation applications in drug development timeline processes. Wednesday 09:45-11:15 |
| I-58 Pauline Traynard Validation of non-compartmental analysis (NCA) and bioequivalence results of PKanalix with respect to Phoenix WinNonLin and SAS. Wednesday 09:45-11:15 |
| I-59 carla troisi Population pharmacokinetics of continuous infusion ampicillin in the treatment of enterococcal infections in adult hospitalised patients Wednesday 09:45-11:15 |
| I-60 Monika Twarogowska A library of parent-metabolite models for the MonolixSuite Wednesday 09:45-11:15 |
| I-62 Marinda van de Kreeke Identifiability of drug effects in turn-over models with increasing complexity Wednesday 09:45-11:15 |
